Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | KLK3 | P07288 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443920 | 0.93 | AR (0.49) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL1443812 | 0.92 | AR (0.48) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL11938775 | 0.91 | AR (0.48) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL1443839 | 0.88 | AR (0.46) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL11938782 | 0.86 | AR (0.51) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL1443924 | 0.86 | AR (0.48) | ARABCG2GABRPGABRDNR1I2 | |
| Faznolutamide SCHEMBL1444059 | 0.85 | AR (0.43) | ARABCG2GABRPGABRDNR1I2 | |
| Faznolutamide SCHEMBL31453007 | 0.85 | AR (0.43) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL1444721 | 0.85 | AR (0.50) | ARABCG2GABRPGABRDNR1I2 | |
| SCHEMBL11939276 | 0.85 | AR (0.50) | ARABCG2GABRPGABRDNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475647-B1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2015-11-04 | — | — | EP | disclosed |
| EP-2475647-B1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-20140315957-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2014-10-23 | — | — | US | disclosed |
| US-20140315957-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2014-10-23 | — | — | US | disclosed |
| US-8809550-B2 | Androgen receptor antagonists and uses thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2014-08-19 | — | — | US | disclosed |
| US-8809550-B2 | Androgen receptor antagonists and uses thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2014-08-19 | — | — | US | disclosed |
| EP-2475647-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | Tong, Youzhi (CN) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172406-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | Tong, Youzhi (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172406-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | Tong, Youzhi (CN) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029392-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029392-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172406-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | AR, SHBG, MUSK | AR 1/4885ABCG2 1759/4885GABRP 1686/4885 |
| US-20140315957-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | AR, SHBG, MUSK | AR 1/4885ABCG2 1759/4885GABRP 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.